Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

Katrine R Schoennemann, Jon K Bjerregaard, Tine Hansen, Karin de Stricker, Morten F Gjerstorff, Helle A Jensen, Lene W Vestermark, Per Pfeiffer

18 Citations (Scopus)

Abstract

Until recently there has been no proven second-line therapy for patients with advanced gastro-esophageal cancer (GEC). Since 2004, Denmark has had a national health program where non-proven therapy can be offered to patients with advanced cancer, after approval by an expert panel appointed by the National Board of Health. This program has accelerated the introduction and implementation of new therapies in Denmark. Inspired by therapy in metastatic colorectal cancer, a combination of cetuximab and irinotecan (Cetiri) was chosen for second-line therapy in GEC patients. We report our experience with Cetiri as second-line therapy in patients with GEC.
Original languageEnglish
JournalGastric Cancer
Volume14
Issue number3
Pages (from-to)219-25
Number of pages7
ISSN1436-3291
DOIs
Publication statusPublished - 2011

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Camptothecin
  • Esophageal Neoplasms
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Organoplatinum Compounds
  • Salvage Therapy
  • Stomach Neoplasms
  • Survival Rate
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum'. Together they form a unique fingerprint.

Cite this